Historique
Périodique
Persistence of antidepressant treatment effects in a pharmacotherapy plus psychotherapy trial for active injection drug users
(Persistance des effets antidépresseurs du traitement chez des usagers de drogues par injection suivant à la fois une pharmacothérapie et une psychothérapie.)
Auteur(s) :
M. D. STEIN ;
SOLOMON D. A. ;
B. J. ANDERSON ;
B. H. HERMAN ;
J. L. ANTHONY ;
R. A. BROWN ;
S. E. RAMSEY ;
I. W. MILLER
Article en page(s) :
346-357
Refs biblio. :
36
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Anglais
Thésaurus mots-clés
DEPRESSION
;
PHARMACOTHERAPIE
;
THERAPIE COMPORTEMENTALE
;
PRISE EN CHARGE
;
SUIVI DU PATIENT
;
EFFICACITE
Note générale :
American Journal on Addictions, 2005, 14, (4), 346-357
Note de contenu :
tabl.
Résumé :
ENGLISH :
The objective of this study was to determine if combined psychotherapy and pharmacotherapy reduces reported depressive symptoms compared to an assessment only condition for active drug injectors over nine months. Using a randomized controlled trial at an outpatient academic research office, the researchers applied psychotherapy (eight sessions of cognitive behavioral therapy) plus pharmacotherapy (citalopram) to active injection drug users with a DSM-IV diagnosis of major depression, dysthymia, substance-induced mood disorder with symptoms persisting for at least three months, or major depression plus dysthymia, and a Modified Hamilton Rating Scale for Depression (MHRSD) score greater than 13. The MHRSD scale scores were then assessed at the completion of three, six, and nine months. Participants (n = 109) were 64% male and 82% Caucasian, with a mean baseline MHRSD score of 20.7. Depression subtypes included major depression only (63%), substance-induced depression (17%), and double-depression (17%). Study retention at nine months was 89%. At the completion of three months of acute treatment, 26% of combined treatment patients (n = 53), compared to 12% of control patients (n = 56), were in remission (p = .047). At both six and nine months, the between-group differences in remission rates and mean MHRSD scores were insignificant, although the overall mean MHRSD score decreased from baseline (p
ENGLISH :
The objective of this study was to determine if combined psychotherapy and pharmacotherapy reduces reported depressive symptoms compared to an assessment only condition for active drug injectors over nine months. Using a randomized controlled trial at an outpatient academic research office, the researchers applied psychotherapy (eight sessions of cognitive behavioral therapy) plus pharmacotherapy (citalopram) to active injection drug users with a DSM-IV diagnosis of major depression, dysthymia, substance-induced mood disorder with symptoms persisting for at least three months, or major depression plus dysthymia, and a Modified Hamilton Rating Scale for Depression (MHRSD) score greater than 13. The MHRSD scale scores were then assessed at the completion of three, six, and nine months. Participants (n = 109) were 64% male and 82% Caucasian, with a mean baseline MHRSD score of 20.7. Depression subtypes included major depression only (63%), substance-induced depression (17%), and double-depression (17%). Study retention at nine months was 89%. At the completion of three months of acute treatment, 26% of combined treatment patients (n = 53), compared to 12% of control patients (n = 56), were in remission (p = .047). At both six and nine months, the between-group differences in remission rates and mean MHRSD scores were insignificant, although the overall mean MHRSD score decreased from baseline (p
Affiliation :
Division of General Internal Medicine, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903. E-mail: msteinlifestan.org
Etats-Unis. United States.
Etats-Unis. United States.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |